Travoprost - CAS 157283-68-6
Catalog number: B0084-059917
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C26H35F3O6
Molecular Weight:
500.55
COA:
Inquire
Targets:
Prostaglandin Receptor
Description:
Travoprost is a potent and selective FP prostaglandin receptor agonist used for the treatment of glaucoma.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-059917 100 mg $198 In stock
B0084-059917 250 mg $398 In stock
Bulk Inquiry
Purity:
>98%
Synonyms:
Travatan; Fluprostenol isopropyl ester; AL-6221; Flu-Ipr
MSDS:
Inquire
InChIKey:
MKPLKVHSHYCHOC-AHTXBMBWSA-N
InChI:
InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
Canonical SMILES:
CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O
1. Deepening of Eyelid Superior Sulcus During Topical Travoprost Treatment
Hee Kyung Yang, Ki Ho Park, Tae-Woo Kim, and Dong Myung Kim. Jpn J Ophthalmol 2009;53:176–179
The time course of eyelid sulcus deepening after begin-ning travoprost seems to be more gradual than that of other side effects, and the deepening was therefore detected only after 1 or 2 years after initiation of travoprost. In addition, the changes were not reversible up to 6 months after dis-continuation, but gradually improved after 15 months. This result is quite different from other side effects, such as hyperpigmentation or hypertrichosis, which develop as early as 1 month after topical travoprost is begun, and are reversed within several months after drug cessation. The same complication of eyelid sulcus deepening caused by bimatoprost appeared and disappeared as soon as 1 month after initiation or discontinuation of the treatment. These differences may not be fully explained by individual differ-ences or different drug actions, and they remain to be elucidated.
2. Bimatoprost 0.03% Versus Travoprost 0.004% in Black Americans With Glaucoma or Ocular Hypertension
Robert J. Noecker. Advances In Therapy. Volume 20 No. 2 March/April 2003
Recent clinical studies have evaluated two of the newest ocular hypotensive agents, bimatoprost and travoprost, in black and nonblack patients with glaucoma or ocular hypertension. Bimatoprost, a prostamide, provided equally potent IOP lowering in both populations. Travoprost, a prostaglandin analogue, was less effec-tive in nonblacks than in blacks. Although the respective phase III results suggest comparable IOP-lowering efficacy in black patients, bimatoprost and travoprost have yet to undergo head-to-head comparisons. Hence, the purpose of this study: to compare the efficacy and safety of these drugs in African-American patients with glaucoma or ocular hypertension.
3. Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension
Norbert Pfeiffer. Graefes Arch Clin Exp Ophthalmol (2011) 249:1065–1071
The first prostaglandin analog available was latanoprost. Travoprost is a newer prostaglandin analog which has been reported to be highly effective both in monotherapy and with adjuncts. Addition of timolol to travoprost resulted in an additional IOP reduction similar to that seen when added to latanoprost. The main aim of this study was to compare the efficacy and safety of timolol maleate 0.5% solution versus brinzolamide 1% when added to travoprost 0.004% in patients with ocular hypertension or primary open-angle glaucoma unsuccessfully controlled with a prostaglandin analog monotherapy.
4. Effect of Travoprost on Intraocular Pressure During 12 Months of Treatment for Normal-Tension Glaucoma
Min Hee Suh, Ki Ho Park, and Dong Myung Kim. Jpn J Ophthalmol 2009;53:18–23
In the present study, travoprost administered daily success-fully reduced IOP in NTG patients. Travoprost treatment for 1 month effectively reduced IOP and then continued to reduce IOP values over the 12-month treatment period. The slight increase in IOP observed between 9 and 12 months was due to the loss of 6 patients to follow-up because their IOP was well controlled at 9 months (Fig. 1). To the best of our knowledge, no study has evaluated the efficacy of travoprost in NTG patients. Thus, the findings of this study expand knowledge of the therapeutic effects of travo-prost in terms of IOP reduction to include NTG as well as OHT and POAG.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Prostaglandin Receptor Products


AM-211 sodium
(CAS: 1263077-74-2)

This active molecular is a potent Prostaglandin D2 receptor antagonists and has been in phase I clinical trials for both COPD (chronic obstructive pulmonary dis...

CAS 415903-37-6 Grapiprant (CJ-023423)

Grapiprant (CJ-023423)
(CAS: 415903-37-6)

Grapiprant, also known as CJ-023,423, RQ-00000007 and AAT-007, is a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic prop...

Terutroban
(CAS: 165538-40-9)

Terutroban is a potent, orally active antagonist of the thromboxane/prostaglandin A2(TP) receptor (IC50 = 16.4 nM). In guinea pigs it also inhibits U 46619 indu...

CAS 752187-80-7 CP 544326

CP 544326
(CAS: 752187-80-7)

CP 544326, also known as taprenepag, is a potent and selective EP(2) receptor agonist. Its EC50 value is 2.8 nM. It is the active acid metabolite of the prodrug...

CAS 58551-69-2 Carboprost tromethamine

Carboprost tromethamine
(CAS: 58551-69-2)

Carboprost tromethamine is the salt of Carboprost, an analogue of naturally occurring prostaglandin F2 alpha (PGF2 alpha). Carboprost activates prostaglandin F ...

CAS 892549-43-8 Mf-63

Mf-63
(CAS: 892549-43-8)

Mf-63 is a selective Microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor. Its IC50 value is 0.9 nM and 1.3 nM for pig mPGES-1 and human mPGES-1 enzyme, r...

CAS 872365-14-5 Fevipiprant

Fevipiprant
(CAS: 872365-14-5)

Fevipipran is a reversible competitive CRTh2 antagonist with IC50 value of 0.44 nM for inhibition of PGD2-induced eosinophil shape change in human whole blood. ...

BGC 20-1531 hydrochloride

BGC 20-1531 hydrochloride is a potent and selective EP4 antagonist (Ki = 3 nM) that displays >2500-fold selectivity for EP4 over EP2 and EP3. BGC 20-1531 inhibi...

Chemical Structure

CAS 157283-68-6 Travoprost

Quick Inquiry

Verification code

Featured Items